188 related articles for article (PubMed ID: 28647402)
1. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.
Martino M; Console G; Russo L; Meliado' A; Meliambro N; Moscato T; Irrera G; Messina G; Pontari A; Morabito F
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):506-512. PubMed ID: 28647402
[TBL] [Abstract][Full Text] [Related]
2. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.
Martino M; Montanari M; Ferrara F; Ciceri F; Scortechini I; Palmieri S; Marktel S; Cimminiello M; Messina G; Irrera G; Offidani M; Console G; Castagna L; Milone G; Bruno B; Tripepi G; Lemoli RM; Olivieri A;
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1026-32. PubMed ID: 24699116
[TBL] [Abstract][Full Text] [Related]
3. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
5. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
Clemmons AB; Anderegg S
J Oncol Pharm Pract; 2017 Jul; 23(5):384-388. PubMed ID: 27000280
[TBL] [Abstract][Full Text] [Related]
6. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
8. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.
Shah N; Cornelison AM; Saliba R; Ahmed S; Nieto YL; Bashir Q; Parmar S; Hosing C; Popat U; Shpall EJ; Champlin RE; Qazilbash M
Eur J Haematol; 2017 Dec; 99(6):532-535. PubMed ID: 28895206
[TBL] [Abstract][Full Text] [Related]
9. Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Mohyuddin GR; Abbasi S; Okoniewski M; McClune B; Abdallah AO; Ganguly S; McGuirk J; Shune L
Eur J Haematol; 2020 Nov; 105(5):571-577. PubMed ID: 32662224
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.
Martino M; Ciavarella S; De Summa S; Russo L; Meliambro N; Imbalzano L; Gallo GA; Moscato T; Messina G; Ferreri A; Cuzzola M; Irrera G; Naso V; Cimminiello M; Console G; Loseto G; Tommasi S; Guarini A
Biol Blood Marrow Transplant; 2018 Mar; 24(3):608-613. PubMed ID: 29032271
[TBL] [Abstract][Full Text] [Related]
11. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma.
Holbro A; Ahmad I; Cohen S; Roy J; Lachance S; Chagnon M; LeBlanc R; Bernard L; Busque L; Roy DC; Sauvageau G; Kiss TL
Biol Blood Marrow Transplant; 2013 Apr; 19(4):547-51. PubMed ID: 23253556
[TBL] [Abstract][Full Text] [Related]
12. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.
Martino M; Lemoli RM; Girmenia C; Castagna L; Bruno B; Cavallo F; Offidani M; Scortechini I; Montanari M; Milone G; Postacchini L; Olivieri A
Bone Marrow Transplant; 2016 Aug; 51(8):1032-40. PubMed ID: 27042841
[TBL] [Abstract][Full Text] [Related]
13. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.
Pierelli L; Berto P; Accorsi P; Milone G; Lopatriello S; Aiello A; Iacopino P; Olivieri A; Rambaldi A; Bosi A
Transfus Apher Sci; 2013 Dec; 49(3):615-22. PubMed ID: 23973731
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
15. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
16. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
17. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample.
Jones JA; Qazilbash MH; Shih YC; Cantor SB; Cooksley CD; Elting LS
Cancer; 2008 Mar; 112(5):1096-105. PubMed ID: 18286506
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
19. Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) - a focus on healthcare resource utilization and cost.
Iida S; Ishida T; Horimoto K; Kazama H; Kim H; Crawford B; Teshima T
Int J Hematol; 2021 Feb; 113(2):271-278. PubMed ID: 33063174
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
